

RESEARCH

Open Access



Excretable, ultrasmall hexagonal NaGdF₄:Yb50% nanoparticles for bimodal imaging and radiosensitization

Jossana A. Damasco^{1,10}, Tymish Y. Ohulchansky^{1,6}, Supriya Mahajan², Guanying Chen^{1,9}, Ajay Singh¹, Hilliard L. Kutscher^{1,7}, Haoyuan Huang³, Steven G. Turowski⁴, Joseph A. Spornyak⁴, Anurag K. Singh⁵, Jonathan F. Lovell³, Mukund Seshadri^{4,8} and Paras N. Prasad^{1*}

*Correspondence:

pnprasad@buffalo.edu

¹ Department of Chemistry and Institute for Lasers, Photonics and Biophotonics, University At Buffalo, The State University of New York, Buffalo, NY 14260, USA
Full list of author information is available at the end of the article

Abstract

Background: In this study, we report on the synthesis, imaging, and radiosensitizing properties of ultrasmall β -NaGdF₄:Yb50% nanoparticles as a multifunctional theranostic platform. The synthesized nanoparticles act as potent bimodal contrast agents with superior imaging properties compared to existing agents used for magnetic resonance imaging (MRI) and computed tomography (CT). Clonogenic assays demonstrated that these nanoparticles can act as effective radiosensitizers, provided that the nanoparticles are taken up intracellularly.

Results: Our ultrasmall β -NaGdF₄:Yb50% nanoparticles demonstrate improvement in T1-weighted contrast over the standard clinical MR imaging agent Gd-DTPA and similar CT signal enhancement capabilities as commercial agent iohexol. A 2 Gy dose of X-ray induced ~20% decrease in colony survival when C6 rat glial cells were incubated with non-targeted nanoparticles (NaGdF₄:Yb50%), whereas the same X-ray dose resulted in a ~60% decrease in colony survival with targeted nanoparticles conjugated to folic acid (NaGdF₄:Yb50%-FA). Intravenous administration of nanoparticles resulted in clearance through urine and feces within a short duration, based on the ex vivo analysis of Gd³⁺ ions via ICP-MS.

Conclusion: These biocompatible and in vivo clearable ultrasmall NaGdF₄:Yb50% are promising candidates for further evaluation in image-guided radiotherapy applications.

Keywords: Gadolinium nanoparticles, Radiosensitizer, Theranostics, MR/CT imaging probes, Glioblastoma

Background

Clinically relevant, multifunctional nanoparticles that combine diagnostic and therapeutic platforms are of high scientific interest, with significant societal impact (Chen et al. 2016,2017; Dasgupta et al. 2020). However, these theranostic nanomaterials often result in complex and large-sized structures to accommodate the various components that provide multi-functionality. In addition, complicated synthesis methods are difficult to reproduce and can be impractical for large-scale processing.



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

To be clinically relevant, nanomaterials need to exhibit biocompatibility and ideally undergo rapid clearance from the body. (Yang et al. 2019) Nanoparticles are primarily taken up and eventually cleared by the reticuloendothelial system (RES) or kidneys. However, retention in the liver or spleen can take up a long time depending on their size and surface chemistry. (Kermanizadeh et al. 2020; Feliu et al. 2016) These accumulations in the RES and the slow elimination, taking months or even years to clear the body, can be problematic for clinical translation. On the other hand, clearance through the kidneys occurs quickly, as the nanoparticles are filtered from the blood and excreted out. This significantly reduces the risk of potential toxicity, which makes the renal clearance pathway an attractive route of elimination. (Du et al. (2018)) However, glomerular filtration is strongly dependent on size, with a hydrodynamic diameter filtration-size threshold of <6 nm. (Longmire et al. 2008) Thus, the development of ultrasmall, biocompatible, multifunctional nanoparticles is of high interest for potential clinical use (Longmire et al. 2008; Xie et al. 2020; Choi et al. 2010).

One of the promising applications of theranostic nanoparticles is their ability to enhance radiotherapeutic efficacy. Radiation therapy (RT) is an integral part of clinical management of most solid tumors, and remains one of the most cost-effective treatments for cancer patients (Retif et al. 2015). However, not all patients respond to RT, and disease recurrence remains a significant clinical problem (Platek et al. 2013).

The use of nanoparticles to 'sensitize' tumors to RT could potentially enable lowering of the total radiation dose administered to patients, without compromising efficacy. Furthermore, radiation-induced normal tissue toxicity often contributes to a poor quality of life (QOL) in patients. Optimal use of these nanoparticles in combination with RT may therefore minimize collateral radiation damage to normal tissues and potentially improve QOL.

In this regard, there is growing interest in the use of metal nanoparticles as radiosensitizers. Upon irradiation, metal nanoparticles, with their high surface area and surface chemistries, have shown intrinsic radiocatalytic activities in water producing reactive oxygen species (ROS), thus, effectively increasing the overall radical concentration. (Guerreiro et al. 2019) Furthermore, interactions of X-ray with metals with high atomic number (high Z) are known to enhance the photoelectric and Compton effects that result in radiation dose-enhancements. (Retif et al. (2015)) Most studies have focused on gold ($Z=79$) nanoparticles and significant evidences have been reported to demonstrate their ability to increase the therapeutic ratio of radiotherapy. (Penninckx et al. (2020); Laprise-Pelletier et al. 2018; Ngwa et al. 2014; Babaei and Ganjalikhani 2014) Hafnium oxide ($Z=72$) developed by NanoBiotix (France) has already shown success in the clinic as efficient radiation enhancers on patients requiring preoperative radiotherapy. (Bonvalot et al. 2019) Other metal nanoparticles that have shown great promise in augmenting radiotherapy include bismuth ($Z=83$) (Deng et al. 2018), platinum ($Z=78$) (Erika et al. 2010; Li et al. 2019), and iron oxide (Klein et al. 2012; Khoei et al. 2014) having both radiosensitizing and hyperthermic (Cassim et al. 2009) properties.

Both gadolinium-based ($Z=64$) and ytterbium-based ($Z=70$) nanoparticles have garnered attention as theranostic platforms. Gd-based nanoparticles have been shown to enhance magnetic resonance (MR) imaging contrast and have been found to induce X-ray dose enhancement, making them ideal candidates for combined imaging and

therapy, and are currently in Phase I clinical trial for the treatment of multiple brain metastases. (Dufort et al. 2019; Duc et al. 2014; Verry et al. 2019) Yb-based nanoparticles have been developed as bimodal probes for X-ray computed tomography (CT) and near infrared-to-near infrared fluorescence imaging. (Xing et al. 2012) The high X-ray attenuation of Yb enabled its use as a theranostic agent, with both tumor imaging and radiosensitization functions. (Xing et al. 2013).

In this study, we present nanoparticles containing Gd and Yb as candidates for combined imaging and therapy in a single ultrasmall nanoplatform for cancer therapy. The combination of Gd and Yb allows for the nanocrystal serving as a bimodal imaging probe for MR and CT examinations. MR imaging is best suited for soft-tissue imaging, while X-ray CT is ideal for hard tissues or bone. In addition, reducing the size of the nanoparticles to sub-5 nm increases the surface Gd^{3+} accessible to H_2O which leads to higher T1 relaxivities in comparison to larger nanoparticles, (Johnson et al. 2011) while allowing complete elimination from the body within days (i.e., 4 days) through hepatic and renal clearance, as revealed from our ICP-MS analysis of Gd^{3+} . The first reported use of combined Gd and Yb as an MR/CT probe was in the form of $NaGdF_4:Yb20\%$ doped with 2% Erbium(Er) for additional optical imaging capability. (He et al. 2011) In addition, the CT signal was enhanced by increasing the amount of Yb from 20 to 80% (i.e., $NaYbF_4:Gd20\%$). (Liu et al. 2012) However, for obtaining the preferred thermodynamically stable hexagonal phase, both these preparations resulted in large-sized nanoparticles (i.e. > 20 nm). In addition, prior to the synthesis of the nanocrystals, an initial step to prepare the lanthanide precursors is needed. Here, we present a more practical and user-friendly approach introducing a single-step method that allows a precise control of size, uniformity, and crystal phase. Because MRI is the more sensitive modality, it is ideal to have a higher ratio of Yb to Gd which would result in much higher X-ray attenuation. On the other hand, increasing the concentration of Yb generally produces larger nanoparticles. (He et al. 2011; Liu et al. 2012; Damasco et al. 2014) Thus, to guarantee that the ultrasmall size is maintained in the hexagonal phase, our nanoparticles were designed with an equimolar amount of Gd^{3+} and Yb^{3+} ions.

To ensure effective radiosensitization, these nanoparticles were modified for targeted delivery by conjugating folic acid to their surface, ensuring optimal cellular uptake by cancer cells, which ultimately significantly decreased the number of surviving colonies following a clinically relevant X-ray exposure. Ultra-small size nanoparticles are also ideal for radiotherapy due to low self-absorption of electrons resulting in higher Auger electron yield. (Hossain and Su 2012) These emitted secondary electrons have very low energy and thus short-range to produce localized cellular damage.

We evaluated the efficacy of this nanoplatform in an *in vitro* clonogenic assay using C6 rat glioblastoma cells. Glioblastoma multiforme (GBM) is a grade IV tumor and represents about 15% of all primary brain tumors. It is the most aggressive and infiltrative form of gliomas, quickly spreading in all parts of the brain (Holland 2000) The average survival for GBM is 12–15 months using the current standard of care treatment, and the determination of treatment response and clinical decision-making are based on the accuracy of radiographic assessment. (Arvold and Reardon 2014) A major factor that contributes to poor prognosis in GBM patients is the limited response to treatment caused by the inability of most chemotherapeutic agents to cross the blood–brain

barrier (BBB). We demonstrate here that the ultrasmall size of the nanoparticles conjugated with folic acid can take advantage of the folate receptor expressed at the BBB (Afzalipour et al. 2019; Wu and Pardridge 1999) to facilitate the transport of the nanoparticles across BBB. Advanced MRI and CT imaging techniques such as dynamic contrast-enhanced (DCE) imaging, which monitors the temporal changes in contrast enhancement in blood vessels and tissues to provide a time-concentration curve, are promising non-invasive methods with moderate-to-high accuracy in stratifying tumors and discriminating recurrent lesions and treatment-related changes. (Abdel Razek et al. 2015,2017; O'Connor et al. 2011; Okuchi et al. 2019) Given the marked signal enhancement on both MR and CT imaging, our nanoparticles could enable accurate diagnosis of disease progression of GBM.


With its facile synthesis, highly uniform size distribution, ultrasmall size and easily tailored surface, these novel nanoparticles present a promising, translatable theranostic platform with high tumor uptake, favorable biodistribution, and route of elimination.

Results

Formation of ultrasmall β -NaGdF₄:Yb50%

Uniform sub-5 nm NaGdF₄:Yb50% nanoparticles in a thermodynamically stable, hexagonal phase (β -phase) were successfully synthesized. Analysis of more than 100 nanoparticles from TEM images reveals a normal size distribution with an average diameter of $3.44 \text{ nm} \pm 0.72 \text{ nm}$ (Fig. 1a–c). The formation of ultrasmall β -NaGdF₄:Yb50% nanoparticles is confirmed by its very broad X-ray diffraction patterns, which conform to the standard XRD peaks of the hexagonal β -phase NaGdF₄ (JCPDS 27–0699) (Fig. 1d). Elemental analysis of Gd and Yb content shows the respective actual molar percentages to be 52.18% and 47.82%, a clear indication that the desired stoichiometric amount of Yb³⁺ ions was successfully doped into the NaGdF₄ nanoparticle.

NaREF₄ (RE = rare earth) nanoparticles are known to exist in two phases, the metastable cubic α -phase and the thermodynamically stable hexagonal β -phase (Mai et al.




2006). This difference in stability has been exploited in the focusing of particle size distribution, wherein the more soluble α -phase nanoparticles serve as sacrificial precursors to form the thermodynamically preferred β -phase with narrow distribution (Dühnen et al. 2015; Naduviledathu Raj et al. 2014; Rinkel et al. 2014). This method typically results in larger nanoparticles, although Haase et al. have successfully synthesized 5.6 nm β -NaYF₄:Yb 20%, Er 2% nanoparticles by heating 10 nm sacrificial α -NaYF₄:Yb 20%, Er 2% (Rinkel et al. 2014). However, a more practical and user-friendly approach is to have a single-step method that will allow precise control of size, uniformity, and crystal phase (Fig. 2).


Surface modification of the nanoparticle surface was achieved through ligand exchange by allowing the nanoparticles in chloroform solution, and the L-cysteine and DTPA anhydride in basic water (pH 9) to mix for 24 h. The hydrodynamic diameter measured by dynamic light scattering (DLS) showed an increase in the hydration shell from 4.1 nm (in hexane) to 5.1 nm (in H₂O) (Additional file 1: Figure S1) after surface modification. TEM images did not show clustering or aggregation of the nanoparticles suspended in H₂O (Additional file 1: Figure S2). This successful coating of the ligands on the nanoparticle surface also provided additional functional groups (i.e., amine and carboxylate) to allow bioconjugation of targeting ligands.

Gd³⁺ leaching, cytotoxicity, and biodistribution

The stability of NaGdF₄ was evaluated by measuring the Gd³⁺ ion leakage from the crystal matrix. An analysis of Gd³⁺ leaching shows less than 0.1% Gd³⁺ ions were present when dialyzed against H₂O. Solutions of DMEM with 10% FBS, and DMEM with 10% FBS supplemented with 10 mM phosphate, incubated at 37 °C, were utilized to mimic physiological conditions and to assess the effect of elevated phosphate levels on the stability of the nanoparticles. After 3 days of dialysis, ~2% of the Gd³⁺ was observed in dialysate; this rose to ~3% at higher phosphate concentrations (Fig. 3a).

The effect of the nanoparticles on cell viability was studied by monitoring the mitochondrial metabolic activity through the standard MTS assay. C6 cells remained 100% viable after 12 and 24 h incubation at up to 1 mg/mL (Fig. 3b). More importantly, cells remained 100% viable even with increased incubation time (48 h), at 125 μ g/mL. It is generally accepted that nanoparticle toxicity is concentration- and time-dependent (Kong et al. 2011; Lewinski et al. 2008). Similarly, further increase in the







concentration of the nanoparticles to 1 mg/mL at prolonged exposure time (i.e., 48 h) resulted in increased cytotoxicity (50% of cell viability).

Passive biodistribution and clearance studies revealed that less than 0.5% of the nanoparticles remained in the organs after 4 days, as detected by ICP-MS (Fig. 3c). After 4 h, 33% of the nanoparticles were eliminated through the urine and 21% through the feces (Fig. 3d). The remaining nanoparticles were eliminated mostly through the feces over a period of 4 days (Fig. 3d).

Nanoparticles for MRI and CT imaging

The potential of these nanoparticles as a bimodal imaging probe for both MR and CT imaging was evaluated by measuring their T1 relaxivity ($r1$) and the Hounsfield unit (HU) values, respectively. The relaxivity of the nanoparticles was compared to Gd-DTPA (Magnevist®) at 25 °C and 37 °C by measuring T1 rates of a series of solutions containing increasing Gd³⁺ molar concentrations (as determined by ICP-OES). There is a linear relationship between the Gd³⁺ concentration and the longitudinal relaxation rate ($1/T1$), and $r1$ values are determined from the slope of the resulting linear plots (Additional file 1: Figure S3). A pseudo-colored, T1-weighted spin echo image (TE/TR = 8.5/500 ms) for saline, 200 µM Gd-DTPA, and nanoparticles (200 µM [Gd]) demonstrates the improvement in T1-weighted contrast of the nanoparticles over the standard clinical MR imaging agent Gd-DTPA (Fig. 4b).



The Hounsfield unit (HU) value, determined from the slope of the linear plot of HU as a function of the concentration, can indicate if the nanoparticles can serve as a CT contrast agent. There is a linear correlation between the increasing contrast agent



concentration and the CT signal intensity for both the commercial agent iohexol and the nanoparticle solution (Fig. 5a and c). The nanoparticles and iohexol show almost identical line slopes (Fig. 5b and d) indicating similar signal enhancement capabilities. Setting the HU value of water as zero, the calculated slope for the HU value for the ultrasmall NaGdF₄:Yb50% is approximately 26 HU while that of the iohexol is about 23 HU.

Nanoparticles as a radiosensitizer

A clonogenic assay was used to investigate the potential of the nanoparticles as radiosensitizers in a rat C6 glioma cell line. To ensure that cell death was not due to any inherent toxicity of the nanoparticles, the concentration was kept at 100 μg/mL, which still maintained more than 90% cell viability even after 48 h incubation (Fig. 3b). Colony formation of the cells without nanoparticles and without X-ray radiation treatment served as control. C6 cells incubated with nanoparticles but not subjected to X-ray radiation did not reduce surviving colonies, confirming that the nanoparticle concentration was not cytotoxic (Fig. 6). Irradiation alone of the cells with a 2 Gy dose did not result in any significant cell reproductive death. Cells treated with non-targeted NaGdF₄:Yb50% nanoparticles showed a 16% decrease in surviving colonies, in comparison to cells treated



only with X-ray radiation. In comparison, targeted NaGdF₄:Yb50%-FA nanoparticles demonstrated superior efficacy with only 40% surviving colonies when treated with 2 Gy radiation (Fig. 6).

Nanoparticles cross the blood–brain barrier

To further test the potential application of these ultras-small nanoparticles to treat brain tumors, the ability to cross the blood–brain barrier (BBB) was explored utilizing a previously reported cell-based two-chamber in vitro transwell model of the BBB (Mahajan et al. 2008; Singh et al. 2016). Both non-targeted and FA-targeted nanoparticles demonstrate the ability to cross the BBB (Fig. 7). After 3 h, only ~5% of the non-targeted NaGdF₄:Yb50% nanoparticles crossed the BBB, whereas ~17% of the targeted NaGdF₄:Yb50%-FA crossed. The rate of cell uptake was very gradual for the non-targeted NaGdF₄:Yb50% nanoparticles, and only ~14% were able to cross in 24 h. The targeted NaGdF₄:Yb50%-FA nanoparticles saturated uptake at 24 h and ~34% of the nanoparticles were able to cross BBB at 24 h. Both the non-targeted and targeted nanoparticle uptake had little further uptake between 24 and 72 h (Fig. 7).

Discussion

To produce uniform ultras-small size nanoparticles utilizing a single-step method, it is critical that sufficient nucleation occurs to ensure uniformity, and the reaction temperature (e.g., 270 °C) is reduced to decrease the particle size (Johnson et al. 2011; Jin et al. 2015; Xing et al. 2014). It is well established that the hexagonal β -phase NaGdF₄ nanoparticles readily form at reaction temperatures below 300 °C (Johnson et al. 2011; Jin

et al. 2015). This is due to the large radius of the light lanthanide Gd^{3+} ion that is more polarizable and susceptible to the electron cloud distortion required for the cubic-to-hexagonal-phase transformation (Damasco et al. 2014; Noculak et al. 2015; Wang et al. 2010). However, incorporation of the smaller Yb^{3+} ions into the $NaGdF_4$ nanoparticles resulted in an increased free-energy barrier with regards to the formation of the hexagonal phase nanoparticles. Thus, significant doping of the Yb^{3+} ion into the host lattice favors the formation of the cubic phase nanoparticles, which are easily produced due to the high surface energy of the ultrasmall nanoparticles. This is in agreement with the results of our synthesis of pure $NaGdF_4$, pure $NaYbF_4$, and $NaGdF_4:Yb50\%$ nanoparticles (Additional file 1: Figure S4). Allowing nucleation at room temperature for 30 min and subsequently growing the nanoparticles at 260 °C for 10 min yielded hexagonal $NaGdF_4$, while both pure $NaYbF_4$ and $NaGdF_4:Yb50\%$ resulted in cubic phase nanoparticles as evidenced by their respective XRD patterns (Additional file 1: Figure S1). One way to achieve hexagonal β - $NaGdF_4:Yb50\%$ is to increase the temperature to 300 °C, but this also leads to formation of larger nanoparticles (~12 nm) (Damasco et al. 2014). Hence, to form hexagonal $NaGdF_4:Yb50\%$, nucleation and growth are allowed to take place for 24 h to facilitate the formation of thermodynamically stable, hexagonal nanocrystals, while still maintaining the nanoparticle growth reaction temperature at 260 °C for 10 min to tune the size of the nanoparticles. Pure $NaYbF_4$ was also synthesized with 24 h nucleation to check if β - $NaYbF_4$ can form under such conditions. The XRD pattern (Additional file 1: Figure S5) revealed a pure cubic α -phase, indicating that the reaction conditions were not sufficient to transform to hexagonal $NaYbF_4$. Cubic nanoparticle formation was expected, since the formulation did not contain Gd^{3+} ions, which have been established to lower the energy barrier for phase transformation of $NaYbF_4$ (Damasco et al. 2014).

To render the β - $NaGdF_4:Yb50\%$ nanoparticles useful for biological applications, it is necessary to modify the hydrophobic oleic-capped surface with a biocompatible, hydrophilic ligand. The proximity of water protons to the surface of the nanoparticles is critical in achieving high T1 relaxivity, which can be controlled through a surface coating strategy. (Johnson et al. 2016) Phase transfer via ligand exchange was then performed to ensure efficient surface hydration. Removal of oleic acid avoids the formation of long hydrophobic chains that could render the Gd on the surface of the nanoparticles inaccessible to water. (Fang et al. 2014) In this case, cysteine-DTPA replaced oleic acid on the surface of the nanoparticles to form a stable monodisperse aqueous suspension. The small increase in the hydrodynamic diameter post-surface modification indicates the formation of a compact hydrophilic surface.

The potential toxicity of the non-targeted nanoparticles was investigated to assess their practical usability in a biological environment. One major challenge in the development of a Gd-based contrast agent is the inherent toxicity of the Gd^{3+} ion when dissociated from its chelate in vivo. (Zhou and Lu 2013) In the nanocrystal form (i.e., $NaGdF_4$), the hexagonal phase provides a stable matrix that eliminates transmetallation with endogenous metal ions (i.e., Cu^{2+} , Zn^{2+} , Fe^{2+}/Fe^{3+}) (Morcos 2008; Rabiet et al. 2014; Telgmann et al. 2012; Wu et al. 2010) and hinders any leaching of toxic, free Gd^{3+} ions. (Chen et al. 2011; Kumar et al. 2009) The very low concentration of Gd^{3+} when dialyzed against H_2O demonstrates the high stability of the nanoparticles against dissolution attributed to

their thermodynamically stable hexagonal phase. (Lisjak et al. 2015) However, the presence of elevated phosphate levels resulted in a significant increase in leakage, although still a low percentage of Gd^{3+} , indicating the stability of the nanoparticles in a physiological environment.

It has been demonstrated that the capping ligand has stabilizing effects and can sequester the free Gd^{3+} ions through chelation. (Xing et al. 2014; Ahrén et al. 2010; Mekuria et al. 2017) To further investigate and minimize the Gd^{3+} leakage, two strategies could be pursued to improve the design of the surface ligand in relation to Gd^{3+} release. First, the amount of DTPA conjugated to cysteine could be optimized. Second, DTPA can be replaced with other polyaminocarboxylate ligands such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and derivatives, which are known to form lanthanide complexes with high kinetic stability (Tei et al. 2015; Zhu and Lever 2002).

No intrinsic cytotoxicity from the nanoparticles was observed at a concentration as high as 125 $\mu\text{g/mL}$, even at prolonged exposure time (i.e., 48 h). In vivo clearance study show that the nanoparticles are cleared from the body within days (i.e., 4 days). Furthermore, the fact that the nanoparticles can be cleared through hepatobiliary excretion indicates a decrease in kidney load compared to commercially available Gd^{3+} chelates for MRI (i.e., Gd-DTPA) (Yu and Zheng 2015) which are primarily cleared renally. This can potentially avoid contrast-induced nephropathy, a form of acute renal failure caused by exposure to the contrast media, and may lower the risk for developing nephrogenic systemic fibrosis, triggered in patients with advanced kidney disease. (Perazella 2009).

After establishing the biocompatibility of the nanoparticles, their ability to be used for dual MR/CT imaging was verified. In vitro experiments revealed a substantially higher T1 relaxivity of the nanoparticles compared to a commercial Gd^{3+} chelate at both room temperature and at physiological temperature (37 °C) (Fig. 4a), which may be attributed to the slower tumbling rate of the nanoparticle than the chelate. (Hou et al. 2013) The higher T1 relaxivity values exhibited by the ultrasmall $\text{NaGdF}_4\text{:Yb50\%}$ nanoparticles compared to clinically utilized Gd-DTPA, and their low r_2/r_1 ratio value falling below 2 (1.47 at $T=25\text{ °C}$ and 1.31 $T=37\text{ °C}$ calculated from Additional file 1: Figure S3) demonstrate their potential to serve as an effective T1 MR imaging contrast agent (Zhang et al. 2018). In addition, the high atomic number of Yb induced enhanced CT signal comparable with iohexol. These results confirm the promise of these nanoparticles in MR/CT multi-modal imaging.

The radiosensitization effect of the ultrasmall $\text{NaGdF}_4\text{:Yb50\%}$ nanoparticles was then assessed in rat C6 glioma cell line. The survival and the reproductive integrity of the irradiated cells with and without nanoparticle treatment were evaluated through colony formation. One strategy to target the delivery of nanoparticles is to exploit the overexpressed folate receptor, found in many cancer cell lines. C6 cells internalize folic acid-conjugated particles through caveolae-mediated endocytosis (Dong et al. 2014). Taking advantage of the highly expressed folate receptors on C6 glioma cells, nanoparticles with conjugated folic acid ($\text{NaGdF}_4\text{:Yb50\%-FA}$) were prepared to improve cellular uptake.

Clonogenic assessment showed increased colony formations with the non-irradiated cells incubated with non-targeted and targeted ultrasmall $\text{NaGdF}_4\text{:Yb50\%}$ nanoparticles (Fig. 6) in comparison to the untreated control cells. When cells are exposed to environmental stress, such as the presence of nanoparticles, autophagy can be induced

as an adaptive response, upregulating expressions of genes and proteins that induce cytoprotection and promote cell survival (Hsu 2012; Tseng and Hsieh 2016; Zahirnyk et al. 2007). Irradiation of cells without nanoparticles did not result in any significant effect on the colony area at 2 Gy dose, suggesting the low intrinsic radiosensitivity of C6 cells (Schueller et al. 2004). Nevertheless, they seemed to form more smaller colonies indicating some effect on their reproductive capacity. On the other hand, both the non-targeted and targeted nanoparticles have clearly shown radiosensitization. These results are in agreement with the recent study investigating the cytotoxicity and radiosensitization of several rare-earth oxide nanoparticles (i.e., Ce, Nd, Gd, and La), wherein Gd_2O_3 nanoparticles have shown significant radiosensitization and have generated additional ROS in U-87 MG cell line upon irradiation, without intrinsic toxicity (Lu et al. 2019). As evidenced by a significant difference in the surviving colonies between the non-targeted (NaGdF₄:Yb50%) and the targeted (NaGdF₄:Yb50%-FA) nanoparticles at the same concentration, it is imperative that the nanoparticles be associated with the cells to induce effective damage. A new study has shown near complete destruction of tumor spheroids of human ovarian cancer (OVCAR8) when incubated with gadolinium loaded mesoporous silica nanoparticles (Gd-MSN) prior to exposure to monochromatic 50.25 keV X-rays (Matsumoto et al. 2019). It is worth noting that the Gd-MSNs accumulated in the lysosomes located close to the cell nucleus. This highlights the importance not only of the energy compatibility made possible using tunable monochromatic beam radiation, but also by the proximity of the radiosensitizers to the nucleus to destroy the DNA of the tumor cells. This is due to the low energy and consequent short-range characteristics of the Auger electrons from the Gd³⁺ and Yb³⁺ ions in the nanoparticles provide for the possibility of a highly targeted radiation therapy.

In several reported studies, folate-conjugated drug delivery systems have shown significant nuclear uptake (Goren et al. 1949; Porta et al. 2013; Wang et al. 2020). Folic acid-modified silica nanoparticles (FAMSNs) with 100 nm diameter have been observed to accumulate in both the nuclei and the cytoplasm, while unmodified MSNs were found only in the cytoplasm, which confirmed the role of folic acid receptors in the nuclear uptake (Porta et al. 2013). The presence of folic acid receptor α (FR α) in the nuclear membrane has been reported (Boshnjaku et al. 2012; Bozard et al. 2010). It has also been demonstrated that in the presence of folic acid, FR α translocates to the nucleus (Boshnjaku et al. 2012; Mohanty et al. 2017) This mechanism of folic acid is highly compatible in the targeted delivery of radiosensitizers. Combined with the additional multi-modal imaging capabilities of the nanoparticles, localization in the tumor can be ensured prior to irradiation; therefore, the damage to the surrounding normal cells is minimized if not completely prevented. Furthermore, *in vitro* transmigration assay confirms that both non-targeted and targeted nanoparticle were able to cross the BBB, with the folic acid-modified nanoparticles being 2.4-fold higher. These results further confirm the effectiveness of using folic acid as a target molecule to facilitate transport through BBB.

This study has several limitations. First, although the equimolar ratio of Gd and Yb has shown to achieve the desired properties of CT and MR contrast enhancement and radiosensitization, an optimal ratio between Gd and Yb can only be determined by preparing these hexagonal ultrasmall nanoparticles with different Gd and Yb ratios. Second, *in vivo* MR and CT imaging still need to be performed to evaluate the efficacy of these

nanoparticles as dual contrast agents. Third, the *in vivo* biodistribution and clearance studies were not performed in GBM-bearing mice to evaluate the percentage and half-life of the nanoparticles that cross the BBB of a diseased animal model. As folate receptors are overexpressed in GBM, it is possible that a higher nanoparticle concentration will be internalized by the brain tumors, which could affect the biodistribution in the brain. A survival study of post-irradiated mice with and without these radiosensitizers have yet to be done to assess their safety and efficacy *in vivo*.

Conclusions

A novel, ultrasmall sub-5 nm NaGdF₄:Yb50% formulation designed to combine imaging and therapy was successfully synthesized and surface modified to render biocompatibility and enhanced cellular uptake. Co-doping of Gd and Yb in equimolar amount allowed the formation of the hexagonal phase of the nanoparticle as well as imparting the nanoparticle with multi-functionality to be used as a bimodal probe for both MR and CT imaging with excellent T1 contrast for MRI and Hounsfield unit (HU) for CT imaging. Bioconjugation of folic acid to the surface of these nanoparticles facilitated BBB crossing and increased cellular uptake to enable efficient radiosensitization effects from the emitted low-energy Auger electrons in brain cancer cells. *In vitro* radiosensitization experiments in rat C6 glioma cells showed the FA-targeted nanoparticles as very promising radiosensitizers. Hence, these ultrasmall nanoparticles should be further developed to serve as a promising theranostic platform for image-guided radiotherapy.

Materials and methods

Materials

Gadolinium chloride hexahydrate (99.999%), ytterbium chloride hexahydrate (99.9%), ammonium fluoride (99.99), sodium hydroxide (97%), oleic acid (90%), 1-octadecene (90%), oleylamine (70%), L-cysteine (97%), diethylenetriaminepentaacetic dianhydride (98%), and H₂O₂ (30%) were purchased from Sigma-Aldrich. Methanol (ACS reagent grade, ≥ 99.8%), hexane (ACS reagent grade, ≥ 98.5%), and chloroform (ACS reagent grade, ≥ 99.8%) were purchased from Fisher Scientific. Gadolinium and ytterbium standards for ICP are from Inorganic Ventures and high-purity nitric acid for quantitative trace metal analysis at the ppb level is from BDH Aristar[®] Plus. All materials were used as received.

Synthesis

Synthesis of ultrasmall α-NaGdF₄:Yb50%

Ultrasmall nanoparticles were synthesized by modification of a previously reported procedure (Johnson et al. 2011; Li and Zhang 2008). To a 100 mL three-neck flask containing 0.5 mmol of GdCl₃ · 6H₂O and 0.5 mmol of YbCl₃ · 6H₂O were added 9 mL of oleic acid and 15 mL octadecene. The mixture was heated to 160 °C and maintained for 1 h under argon gas with constant stirring and then cooled to room temperature. A solution of methanol (10 mL) containing 4 mmol NH₄F and 2.5 mmol NaOH was added and the mixture was stirred for 30 min. The temperature is then increased to 100 °C and maintained for 30 min to remove methanol. The solution was then heated at 260 °C for 10 min before cooling to room temperature. The nanoparticles were collected by adding

an excess amount of ethanol and centrifuged at 7000 rcf for 5 min. The precipitate was washed with ethanol and finally dispersed in 10 mL hexane for further uses.

Synthesis of ultrasmall β -NaGdF₄:Yb50%

Ultrasmall nanoparticles were synthesized following the procedure described for α -NaGdF₄:Yb50%, except the solution was stirred for 24 h after the addition of methanol solution (10 mL) containing NH₄F (4 mmol) and NaOH (2.5 mmol).

Synthesis of ultrasmall β -NaGdF₄

Ultrasmall nanoparticles were synthesized following the procedure described for α -NaGdF₄:Yb50%, except 1.0 mmol of GdCl₃ · 6H₂O was used.

Synthesis of ultrasmall α -NaYbF₄

6H₂O, resulted in cubic ultrasmall nanoparticles only.

Ligand exchange surface modification

L-Cysteine (60 mg) and diethylenetriaminepentaacetic (DTPA) dianhydride (20 mg) were dissolved in 30 mL H₂O at pH 9 in a 100 mL round-bottom flask. To this aqueous solution was added 10 mL chloroform solution containing 10 mg of the oleic-capped ultrasmall nanoparticles. The biphasic mixture was stirred vigorously overnight at room temperature to facilitate the transfer of the nanoparticle to the water phase. Excess ligand was removed by twice centrifugation using Vivaspinn-20 centrifugal filters (10 kDa MWCO) at 3000 rcf for 15 min and the collected nanoparticles were redispersed in water and filtered through a 0.2 μ m syringe filter.

Folic acid functionalized ultrasmall nanoparticles (FA-NaGdF₄:Yb50%)

Five hundred microliters of folic acid dissolved in DMSO (25 mg/mL) in the presence of triethylamine (6.25 μ L) was incubated with 6.5 mg of NHS and 6.25 mg of DCC in the dark overnight and then passed through a 0.2 μ m filter. The resulting NHS-activated folic acid was then covalently linked to the amino surface of the nanoparticles provided by cysteine ligand by incubating overnight. The resulting NaGdF₄:Yb50%-FA was centrifuged at 16,000 rcf for 15 min, washed twice and stored in 1 mL H₂O for future use.

Characterization

The size and the morphology of the resulting nanoparticles were characterized by transmission electron microscopy (TEM) using a JEM-2010 microscope at an acceleration voltage of 200 kV. The hydrodynamic size was determined using Malvern Zetasizer NanoZS90. Powder X-ray diffraction (XRD) patterns were recorded by a RigakuUltima IV diffractometer, using Cu K α radiation (λ = 0.15418 nm). The 2 θ angle of the XRD spectra was recorded at a scanning rate of 1°/min. Inductively coupled plasma-optical emission spectrometer (ICP-OES) analysis was performed using a Thermo Scientific iCAP 6000 instrument. CT tests were performed on microCTInveon model scanner (Siemens Medical Solutions USA, Inc.). T1 and T2 rates of the nanoparticles were measured on a 4.7 T preclinical MR scanner using increasing concentrations at both 25 °C and 37 °C with an inversion-recovery, balanced steady-state free precession (IR-bSSFP)

sequence, and a multiecho CPMG scan, respectively, as described elsewhere. (Dorazio et al. 2011) T1 and T2 relaxivities ($\text{mM}^{-1} \cdot \text{s}^{-1}$) of the nanoparticles were compared to the commercially available Gd-DTPA contrast agent, Magnevist[®].

Elemental analysis using ICP-OES

Acid digestion was performed by dissolving 0.15 mg of the nanoparticles in 0.5 mL concentrated high-purity HNO_3 acid overnight and diluting with a 2% HNO_3 solution to a total volume of 15 mL. The single element standards were prepared with the same acid solution.

Gd³⁺ ion leaching

The nanoparticles (5 mL, 1 mM Gd) were loaded into a dialysis tubing (Spectrum, 3.5 kD cut-off) and incubated in H_2O , or DMEM with 10% fetal bovine serum (FBS), or DMEM with 10% FBS supplemented with 10 mM phosphate, at 37 °C under sink conditions, with rocking for 3 days. The amount of released Gd³⁺ ions in each solution was measured using ICP-OES.

Biodistribution and clearance

Animal experiments were performed in compliance with guidelines set by the University at Buffalo Institutional Animal Care and Use Committee. Female CD-1 mice were injected intravenously via tail vein with the nanoparticles in 5% dextrose in water at a dose of 2 mg/kg and housed in metabolic cages for 4 days with free access to water and a standard laboratory diet. Urine and feces were collected separately every 4 h and the mice were sacrificed after 96 h through cervical dislocation. Feces and organs including liver, spleen, kidney, brain, heart, and lungs were harvested, frozen, and weighed prior to digestion. The urine, feces, and isolated organs were individually placed in a screw cap polypropylene sample tube and to each were added 3 mL of concentrated nitric acid and 2 mL peroxide (30% by weight) and pre-digested for 24 h. The tubes were then placed in a sonicated water bath for a total of 8 h until the samples were completely dissolved. After digestion, each sample was diluted to 100 mL with a 2% solution of nitric acid. The samples were then passed through a 0.2 μm filter and the Gd content was quantified with inductively coupled plasma mass spectrometry (ICP-MS) utilizing a Thermo Scientific XSERIES 2 ICP-MS Single Quadrupole Mass Spectrometer.

Cytotoxicity assay

Cell viability was assessed by the PromegaCellTiter 96[®] AQ_{ueous} One Solution Cell Proliferation (MTS) Assay. C6 cells were seeded into a 96-well flat-bottom microplate (c.a. 10,000 cells/well) at 37 °C and 5% CO_2 and allowed to attach to the bottom of the microplate overnight. The cells were then treated with different concentrations of NaGdF₄:Yb50% nanoparticles for 12, 24, and 48 h. After the treatment, the cellular medium was changed to remove the nanoparticles and cell debris, and the AQ_{ueous} One Solution reagent (20 μl /well) was added to the cells and incubated for 4 h. Finally, the absorbance was measured at 490 nm using a microplate reader (Opsys MR microplate reader) to determine the percentage of viable cells in the culture relative to the control wells without nanoparticle treatment.

Clonogenic assay

Clonogenic assay was performed by growing C6 cells in 6-well plates to 90% confluence and were treated with 100 µg/mL concentration of the nanoparticles overnight. Afterward, cells were irradiated with a 2 Gy X-ray dose using the Faxitron® RX-650 X-ray irradiator at a dose rate of 0.5 Gy/min delivered using 130 kV energy. Plates were then incubated for 4 h at 37 °C in 5% CO₂, and the cells were subsequently harvested and counted. To assess colony formation, cells were then re-plated at 1000 cells/well in 6-well plates and allowed to form colonies consisting of 50 cells. Colonies were then gently washed with Hank's Balanced Salt Solution (Gibco® HBSS) and fixed with ice-cold methanol for 10 min, rinsed once again with HBSS, and stained with a 0.5% crystal violet solution for another 10 min. Plates were then rinsed with H₂O to remove excess stain and were left to dry at room temperature. Images of the plates were then acquired and saved in the tagged image file format (Tiff). The colony area for each plate was then measured using the Colony Area plugin (Guzmán et al. 2014) in ImageJ. Surviving colonies were normalized against control wells without nanoparticle treatment.

In vitro BBB transmigration assay

We made and validated a cell-based in vitro transwell model of the BBB in our laboratory and used it to examine BBB properties like quantitative permeability and transendothelial migration of nanoparticles. Our 2D in vitro BBB model consists of a two-chamber transwell system in a 12-well culture plate with the upper (luminal) compartment separated from the lower (abluminal) by a semipermeable membrane (polyethylene terephthalate, PET) insert on which the human brain microvascular endothelial cells (BMVECs) were grown to confluency on the upper side, while a confluent layer of normal human astrocytes (NHAs) was grown on the underside. After tight BBB formation was confirmed by the transendothelial electrical resistance (TEER) measurement, the dispersed nanoparticles (100 µg/mL media) were added to the upper chamber (luminal) and incubated at 37 °C in 5% CO₂. Media from the lower chamber (abluminal) were collected at 1, 5, 24, 48, and 72 h incubation times, and the Gd content was measured using ICP-OES. Percent transmigration was calculated relative to the initial Gd concentration of the media with 100 µg/mL nanoparticles. The TEER was measured again after their crossing of the BBB to make sure that the transmigration was not due to the compromise of BBB.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12645-021-00075-x>.

Additional file 1. Additional figures.

Abbreviations

MRI: Magnetic resonance imaging; CT: Computed tomography; RT: Radiotherapy; GBM: Glioblastoma; BBB: Blood–brain barrier; FBS: Fetal bovine serum; DMEM: Dulbecco's modified Eagle medium; DTPA: Diethylenetriaminepentaacetic; FA: Folic acid; MTS: 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.

Acknowledgements

Not applicable.

Authors' contributions

All authors listed have made substantial, direct, and intellectual contributions to the work discussed in this publication. JAD, TYO, SM, GC, and PNP designed the study. JAD, SM, AS, HLH, HH, STG, and JAS performed the experiments and analyzed the data. SM, JFL, and AKS provided resources to ensure completion of the project. MS and PNP provided the funding. PNP supervised the study. All authors discussed the results and contributed to the final manuscript. All authors read and approved the final manuscript.

Funding

The work at the Institute For Lasers, Photonics and Biophotonics at The University at Buffalo was supported by funds provided by the office of Vice President for Research and Economic Development. This work utilized shared resources at Roswell Park Comprehensive Cancer Center supported the NCI Cancer Center Support Grant P30CA016156. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 and the Roswell Park Alliance Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its additional information on file).

Ethics approval and consent to participate

Animal experiments were performed in compliance with guidelines set by the University at Buffalo Institutional Animal Care and Use Committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Chemistry and Institute for Lasers, Photonics and Biophotonics, University At Buffalo, The State University of New York, Buffalo, NY 14260, USA. ² Department of Medicine, Division of Allergy, Immunology and Rheumatology, University At Buffalo, The State University of New York, Buffalo, NY 14203, USA. ³ Department of Biomedical Engineering, University At Buffalo, The State University of New York, Buffalo, NY 14260, USA. ⁴ Translational Imaging Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. ⁵ Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. ⁶ College of Optoelectronic Engineering, College of Physics and Optoelectronic Engineering, Shenzhen University, 518060 Shenzhen, People's Republic of China. ⁷ Department of Anesthesiology, University At Buffalo, The State University of New York, Buffalo, NY 14214, USA. ⁸ Department of Oral Oncology/Dentistry and Maxillofacial Prosthetics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. ⁹ School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, Heilongjiang 15001, People's Republic of China. ¹⁰ Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Received: 29 August 2020 Accepted: 10 January 2021

Published online: 05 February 2021

References

- Abdel Razek AA, Gaballa G, Ashamalla G, Alashry MS, Nada N. Dynamic susceptibility contrast perfusion-weighted magnetic resonance imaging and diffusion-weighted magnetic resonance imaging in differentiating recurrent head and neck cancer from postradiation changes. *J Comput Assist Tomogr*. 2015;39:849–54.
- Abdel Razek AA, Samir S, Ashamalla GA. Characterization of parotid tumors with dynamic susceptibility contrast perfusion-weighted magnetic resonance imaging and diffusion-weighted MR imaging. *J Comput Assist Tomogr*. 2017;41:131–6.
- Afzalipour R, Khoei S, Khoee S, Shirvalilou S, Jamali Raoufi N, Motevalian M, Karimi MR. Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. *ACS Biomaterials Sci Eng*. 2019;5:6000–11.
- Ahrén M, Selegård L, Klasson A, Söderlind F, Abrikossova N, Skoglund C, Bengtsson T, Engström M, Käll P-O, Uvdal K. Synthesis and characterization of pegylated GD2O3 nanoparticles for MRI contrast enhancement. *Langmuir*. 2010;26:5753–62.
- Arnold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. *Clin Interv Aging*. 2014;9:357–67.
- Babaei M, Ganjalikhani M. The potential effectiveness of nanoparticles as radio sensitizers for radiotherapy. *Biol Impacts*. 2014;4:15–20.
- Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (ActInSarc): a multicentre, phase 2–3, randomised, controlled trial. *Lancet Oncol* 2019; 20:1148–1159.
- Boshnjaku V, Shim K-W, Tsurubuchi T, Ichi S, Szany EV, Xi G, Mania-Farnell B, McLone DG, Tomita T, Mayanil CS. Nuclear localization of folate receptor alpha: a new role as a transcription factor. *Scientific reports*. 2012;2:980–980.

- Bozard BR, Ganapathy PS, Duplantier J, Mysona B, Ha Y, Roon P, Smith R, Goldman ID, Prasad P, Martin PM, et al. Molecular and Biochemical Characterization of Folate Transport Proteins in Retinal Müller Cells. *Invest Ophthalmol Vis Sci*. 2010;51:3226–35.
- Cassim SM, Giustini AJ, Petryk AA, Strawbridge RA, Hoopes PJ: Iron Oxide Hyperthermia And Radiation Cancer Treatment. *Proceedings of SPIE--the International Society for Optical Engineering* 2009, 7181:718100.
- Chen G, Ohulchanskyy TY, Law WC, Agren H, Prasad PN. Monodisperse NaYbF₄: Tm³⁺/NaGdF₄ core/shell nanocrystals with near-infrared to near-infrared upconversion photoluminescence and magnetic resonance properties. *Nanoscale*. 2011;3:2003–8.
- Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy. *Chem Rev*. 2016;116:2826–85.
- Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. *Nat Rev Materials*. 2017;2:17024.
- Choi HS, Liu W, Liu F, Nasr K, Misra P, Bawendi MG, Frangioni JV. Design Considerations for Tumor-Targeted Nanoparticles. *Nat Nanotechnol*. 2010;5:42–7.
- Damasco JA, Chen G, Shao W, Ågren H, Huang H, Song W, Lovell JF, Prasad PN. Size-Tunable and Monodisperse Tm³⁺/Gd³⁺-Doped Hexagonal NaYbF₄ Nanoparticles with Engineered Efficient Near Infrared-to-Near Infrared Upconversion for In Vivo Imaging. *ACS Appl Mater Interfaces*. 2014;6:13884–93.
- Dasgupta A, Biancacci I, Kiessling F, Lammers T. Imaging-assisted anticancer nanotherapy. *Theranostics*. 2020;10:956–67.
- Deng J, Xu S, Hu W, Xun X, Zheng L, Su M. Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced X-ray radiation therapy of breast cancer. *Biomaterials*. 2018;154:24–33.
- Dong S, Cho HJ, Lee YW, Roman M. Synthesis and cellular uptake of folic acid-conjugated cellulose nanocrystals for cancer targeting. *Biomacromol*. 2014;15:1560–7.
- Dorazio SJ, Tsitovich PB, Sifers KE, Sperryak JA, Morrow JR. Iron(II) PARACEST MRI Contrast Agents. *J Am Chem Soc*. 2011;133:14154–6.
- Du B, Yu M, Zheng J. Transport and interactions of nanoparticles in the kidneys. *Nat Rev Materials*. 2018;3:358–74.
- Dufort S, Appelboom G, Verry C, Barbier EL, Lux F, Bräuer-Krisch E, Sancey L, Chang SD, Zhang M, Roux S, et al. Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. *J Clin Neurosci*. 2019;67:215–9.
- Dühren S, Rinkel T, Haase M. Size Control of Nearly Monodisperse β-NaGdF₄ Particles Prepared from Small α-NaGdF₄ Nanocrystals. *Chem Mater*. 2015;27:4033–9.
- Erika P, Samuel L, Hynd R, Noriko U, Katsumi K, Yoshiya F, Le Claude S, Sandrine L. Platinum nanoparticles: a promising material for future cancer therapy? *Nanotechnology*. 2010;21:085103.
- Fang J, Chandrasekharan P, Liu XL, Yang Y, Lv YB, Yang CT, Ding J. Manipulating the surface coating of ultra-small Gd₂O₃ nanoparticles for improved T1-weighted MR imaging. *Biomaterials*. 2014;35:1636–42.
- Feliu N, Docter D, Heine M, del Pino P, Ashraf S, Kolosnjaj-Tabi J, Macchiarini P, Nielsen P, Alloyeau D, Gazeau F, et al. In vivo degeneration and the fate of inorganic nanoparticles. *Chem Soc Rev*. 2016;45:2440–57.
- Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. *Clin Cancer Res*. 1999;5:2000–6.
- Guerreiro A, Chatterton N, Crabb EM, Golding JP. A comparison of the radiosensitisation ability of 22 different element metal oxide nanoparticles using clinical megavoltage X-rays. *Cancer Nanotechnology*. 2019;10:10.
- Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays. *PLoS ONE*. 2014;9:e92444.
- He M, Huang P, Zhang C, Hu H, Bao C, Gao G, He R, Cui D. Dual phase-controlled synthesis of uniform lanthanide-doped NaGdF₄ upconversion nanocrystals via an oa/ionic liquid two-phase system for in vivo dual-modality imaging. *Adv Func Mater*. 2011;21:4470–7.
- Holland EC. Glioblastoma multiforme: The terminator. *Proc Natl Acad Sci USA*. 2000;97:6242–4.
- Hossain M, Su M. Nanoparticle location and material dependent dose enhancement in X-ray radiation therapy. *J Phys Chem C*. 2012;116:23047–52.
- Hou Y, Qiao R, Fang F, Wang X, Dong C, Liu K, Liu C, Liu Z, Lei H, Wang F, Gao M. NaGdF₄ nanoparticle-based molecular probes for magnetic resonance imaging of intraperitoneal tumor xenografts in vivo. *ACS Nano*. 2013;7:330–8.
- Hsu S-h, Ho T-T, Tseng T-C. Nanoparticle uptake and gene transfer efficiency for MSCs on chitosan and chitosan-hyaluronan substrates. *Biomaterials*. 2012;33:3639–50.
- Jin X, Fang F, Liu J, Jiang C, Han X, Song Z, Chen J, Sun G, Lei H, Lu L. An ultrasmall and metabolizable PEGylated NaGdF₄: Dy nanoprobe for high-performance T1/T2-weighted MR and CT multimodal imaging. *Nanoscale*. 2015;7:15680–8.
- Johnson NJJ, Oakden W, Staniszc GJ, Scott Prosser R, van Veggel FCJM. Size-tunable, ultrasmall NaGdF₄ nanoparticles: insights into their T1 MRI contrast enhancement. *Chem Mater*. 2011;23:3714–22.
- Johnson NJJ, He S, Nguyen Huu VA, Almutairi A. Compact micellization: a strategy for ultrahigh T1 magnetic resonance contrast with gadolinium-based nanocrystals. *ACS Nano*. 2016;10:8299–307.
- Kermanizadeh A, Powell LG, Stone V. A review of hepatic nanotoxicology – summation of recent findings and considerations for the next generation of study designs. *J Toxicol Environ Health B*. 2020;23:137–76.
- Khoei S, Mahdavi SR, Fakhimikabir H, Shakeri-Zadeh A, Hashemian A. The role of iron oxide nanoparticles in the radiosensitization of human prostate carcinoma cell line DU145 at megavoltage radiation energies. *Int J Radiat Biol*. 2014;90:351–6.
- Klein S, Sommer A, Distel LVR, Neuhuber W, Kryschi C. Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation. *Biochem Biophys Res Commun*. 2012;425:393–7.
- Kong B, Seog JH, Graham LM, Lee SB. Experimental considerations on the cytotoxicity of nanoparticles. *Nanomedicine (London, England)*. 2011;6:929–41.
- Kumar R, Nyk M, Ohulchanskyy TY, Flask CA, Prasad PN. Combined Optical and MR Bioimaging Using Rare Earth Ion Doped NaYF₄ Nanocrystals. *Adv Func Mater*. 2009;19:853–9.
- Laprise-Pelletier M, Simão T, Fortin M-A. Gold Nanoparticles in Radiotherapy and Recent Progress in Nanobrachytherapy. *Advanced Healthcare Materials*. 2018;7:1701460.

- Le Duc G, Roux S, Paruta-Tuarez A, Dufort S, Brauer E, Marais A, Truillet C, Sancey L, Perriat P, Lux F, Tillement O. Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. *Cancer Nanotechnology*. 2014;5:4.
- Lewinski N, Colvin V, Drezek R. Cytotoxicity of Nanoparticles. *Small*. 2008;4:26–49.
- Li Z, Zhang Y. An efficient and user-friendly method for the synthesis of hexagonal-phase NaYF₄:Yb, Er/Tm nanocrystals with controllable shape and upconversion fluorescence. *Nanotechnology*. 2008;19:345606.
- Li Y, Yun K-H, Lee H, Goh S-H, Suh Y-G, Choi Y. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. *Biomaterials*. 2019;197:12–9.
- Lisjak D, Plohl O, Ponikvar-Svet M, Majaron B. Dissolution of upconverting fluoride nanoparticles in aqueous suspensions. *RSC Advances*. 2015;5:27393–7.
- Liu Y, Ai K, Liu J, Yuan Q, He Y, Lu L. A High-Performance Ytterbium-Based Nanoparticulate Contrast Agent for In Vivo X-Ray Computed Tomography Imaging. *Angew Chem Int Ed*. 2012;51:1437–42.
- Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. *Nanomedicine (London, England)*. 2008;3:703–17.
- Lu VM, Crawshaw-Williams F, White B, Elliot A, Hill MA, Townley HE. Cytotoxicity, dose-enhancement and radiosensitization of glioblastoma cells with rare earth nanoparticles. *Artif Cells Nanomed Biotechnol*. 2019;47:132–43.
- Mahajan SD, Aalinkhel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, Qi M, Toh J, Xu G, Prasad PN, Schwartz SA. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. *Brain Res*. 2008;1203:133–48.
- Mai H-X, Zhang Y-W, Si R, Yan Z-G, Sun L-d, You L-P, Yan C-H: High-quality sodium rare-earth fluoride nanocrystals: controlled synthesis and optical properties. *J Am Chem Soc*. 2006;128:6426–36.
- Matsumoto K, Saitoh H, Doan TLH, Shiro A, Nakai K, Komatsu A, Tsujimoto M, Yasuda R, Kawachi T, Tajima T, Tamanoi F. Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. *Sci Rep*. 2019;9:13275.
- Mekuria SL, Debele TA, Tsai H-C. Encapsulation of gadolinium oxide nanoparticle (Gd₂O₃) Contrast Agents in PAMAM dendrimer templates for enhanced magnetic resonance imaging in vivo. *ACS Appl Mater Interfaces*. 2017;9:6782–95.
- Mohanty V, Siddiqui MR, Tomita T, Mayanil CS. Folate receptor alpha is more than just a folate transporter. *Neurogenesis*. 2017;4:e1263717.
- Morcos SK. Extracellular gadolinium contrast agents: Differences in stability. *Eur J Radiol*. 2008;66:175–9.
- Naduviledathu Raj A, Rinkel T, Haase M. Ostwald Ripening, Particle Size Focusing, and Decomposition of Sub-10 nm NaREF₄ (RE = La, Ce, Pr, Nd) Nanocrystals. *Chem Mater*. 2014;26:5689–94.
- Ngwa W, Kumar R, Sridhar S, Korideck H, Zygmanski P, Cormack RA, Berbeco R, Makrigiorgos GM. Targeted radiotherapy with gold nanoparticles: current status and future perspectives. *Nanomedicine (London, England)*. 2014;9:1063–82.
- Noculak A, Podhorodecki A, Pawlik G, Banski M, Misiewicz J. Ion-ion interactions in [small beta]-NaGdF₄:Yb³⁺, Er³⁺ nanocrystals - the effect of ion concentration and their clustering. *Nanoscale*. 2015;7:13784–92.
- O'Connor JPB, Tofts PS, Miles KA, Parkes LM, Thompson G, Jackson A: Dynamic contrast-enhanced imaging techniques: CT and MRI. *Br J Radiol* 2011, 84 Spec No 2:S112–S120.
- Okuchi S, Rojas-García A, Ulyte A, Lopez I, Ušinskienė J, Lewis M, Hassanein SM, Sanverdi E, Golay X, Thust S, et al. Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis. *Cancer Med*. 2019;8:5564–73.
- Penninckx S, Heuskin AC, Michiels C, Lucas S. Gold nanoparticles as a potent radiosensitizer: a transdisciplinary approach from physics to patient. *Cancers (Basel)* 2020; 12: 1.
- Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. *Clin J Am Soc Nephrol*. 2009;4:461–9.
- Platek ME, McCloskey SA, Cruz M, Burke MS, Reid ME, Wilding GE, Rigual NR, Popat SR, Loree TR, Gupta V, et al. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. *Head Neck*. 2013;35:684–8.
- Porta F, Lamers GEM, Morrhayim J, Chatzopoulou A, Schaaf M, den Dulk H, Backendorf C, Zink JJ, Kros A. Folic acid-modified mesoporous silica nanoparticles for cellular and nuclear targeted drug delivery. *Adv Healthcare Materials*. 2013;2:281–6.
- Rabiet M, Letouzet M, Hassanzadeh S, Simon S. Transmetalation of Gd-DTPA by Fe³⁺, Cu²⁺ and Zn²⁺ in water: batch experiments and coagulation-flocculation simulations. *Chemosphere*. 2014;95:639–42.
- Retif P, Pinel S, Toussaint M, Frochot C, Choukhat R: Nanoparticles for radiation therapy enhancement: the key parameters. *Theranostics* 2015.
- Rinkel T, Nordmann J, Raj AN, Haase M. Ostwald-ripening and particle size focussing of sub-10 nm NaYF₄ upconversion nanocrystals. *Nanoscale*. 2014;6:14523–30.
- Schueler P, Puettmann S, Micke O, Senner V, Schaefer U, Willich N. Selenium influences the radiation sensitivity of C6 rat glioma cells. *Anticancer Res*. 2004;24:2913–7.
- Singh A, Kim W, Kim Y, Jeong K, Kang CS, Kim Y, Koh J, Mahajan SD, Prasad PN, Kim S. Multifunctional Photonics Nanoparticles for Crossing the Blood-Brain Barrier and Effecting Optically Trackable Brain Theranostics. *Adv Func Mater*. 2016;26:7057–66.
- Tei L, Baranyai Z, Gaino L, Forgacs A, Vagner A, Botta M. Thermodynamic stability, kinetic inertness and relaxometric properties of monoamide derivatives of lanthanide(III) DOTA complexes. *Dalton Trans*. 2015;44:5467–78.
- Telgmann L, Wehe CA, Kunemeyer J, Bulter AC, Sperling M, Karst U. Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements. *Anal Bioanal Chem*. 2012;404:2133–41.
- Tseng T-C, Hsieh F-Y, Hsu S-h: Increased cell survival of cells exposed to superparamagnetic iron oxide nanoparticles through biomaterial substrate-induced autophagy. *Biomaterials Sci*. 2016;4:670–7.

- Verry C, Sancey L, Dufort S, Le Duc G, Mendoza C, Lux F, Grand S, Arnaud J, Quesada JL, Villa J, et al. Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. *BMJ Open*. 2019;9:e023591.
- Wang F, Han Y, Lim C, Lu Y, Wang J, Xu J, Chen H, Zhang C, Hong M, Liu X. Simultaneous phase and size control of upconversion nanocrystals through lanthanide doping. *Nature*. 2010;463:1061–5.
- Wang M, Long J, Zhang S, Liu F, Zhang X, Zhang X, Sun L, Ma L, Yu C, Wei H. Folate-Targeted Anticancer Drug Delivery via a Combination Strategy of a Micelle Complex and Reducible Conjugation. *ACS Biomaterials Science & Engineering*. 2020;6:1565–72.
- Wu D, Pardridge WM. Blood-brain barrier transport of reduced folic acid. *Pharm Res*. 1999;16:415–9.
- Wu X, Zong Y, Ye Z, Lu Z-R. Stability and Biodistribution of a Biodegradable Macromolecular MRI Contrast Agent Gd-DTPA Cystamine Copolymers (GDCC) in Rats. *Pharm Res*. 2010;27:1390–7.
- Xie M, Xu Y, Huang J, Li Y, Wang L, Yang L, Mao H. Going even smaller: engineering sub-5 nm nanoparticles for improved delivery, biocompatibility, and functionality. *WIREs Nanomed Nanobiotechnol*. 2020; 1:e1644.
- Xing H, Bu W, Ren Q, Zheng X, Li M, Zhang S, Qu H, Wang Z, Hua Y, Zhao K, et al. A NaYbF₄: Tm³⁺ nanoprobe for CT and NIR-to-NIR fluorescent bimodal imaging. *Biomaterials*. 2012;33:5384–93.
- Xing H, Zheng X, Ren Q, Bu W, Ge W, Xiao Q, Zhang S, Wei C, Qu H, Wang Z, et al. Computed tomography imaging-guided radiotherapy by targeting upconversion nanocubes with significant imaging and radiosensitization enhancements. *Sci Rep*. 2013;3:1751.
- Xing H, Zhang S, Bu W, Zheng X, Wang L, Xiao Q, Ni D, Zhang J, Zhou L, Peng W, et al. Ultrasmall NaGdF₄ Nanodots for Efficient MR Angiography and Atherosclerotic Plaque Imaging. *Adv Mater*. 2014;26:3867–72.
- Yang G, Phua SZF, Bindra AK, Zhao Y. Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications. *Adv Mater*. 2019;31:1805730.
- Yu M, Zheng J. Clearance pathways and tumor targeting of imaging nanoparticles. *ACS Nano*. 2015;9:6655–74.
- Zabirnyk O, Yezhelyev M, Seleverstov O. Nanoparticles as a novel class of autophagy activators. *Autophagy*. 2007;3:278–81.
- Zhang W, Liu L, Chen H, Hu K, Delahunty I, Gao S, Xie J. Surface impact on nanoparticle-based magnetic resonance imaging contrast agents. *Theranostics*. 2018;8:2521–48.
- Zhou Z, Lu Z-R. Gadolinium-based contrast agents for MR cancer imaging. *Wiley Interdiscipl Rev Nanomed Nanobiotechnol*. 2013;5:1–18.
- Zhu X, Lever SZ. Formation kinetics and stability studies on the lanthanide complexes of 1,4,7,10-tetraazacyclododecane-N, N', N''-tetraacetic acid by capillary electrophoresis. *Electrophoresis*. 2002;23:1348–56.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

